Drug
SR 142801 clinical trials
Also written Osanetant.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How studies write it
Studies that test it under each name
Other names
- Osanetant
- 3
Studies by the year they started
3 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 2
University of Kansas Medical Center (2) · Acer Therapeutics Inc. (1)
Related medicines
As reviewed, each with the page that says it.
- One of Antipsychotic Agents source
Studies
Open first, then newest update. How each study uses SR 142801 is read from its arms, and is right about nine times in ten.
Testing it · 3
- Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With MenopauseCompletedPhase 1/2Acer Therapeutics Inc.NCT05325775Written as ACER-801 50 mg BID
- Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the ProstateTerminatedEarly Phase 1University of Kansas Medical CenterNCT05607342Written as Osanetant
- Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the ProstateWithdrawnEarly Phase 1University of Kansas Medical CenterNCT05647447Written as Osanetant
Codes
What other systems call SR 142801 · ClinicalTrials.gg INT003825
- MeSH (NLM) C091554SR 142801Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) K7G81N94DTOSANETANTConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C091554 | SR 142801 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | K7G81N94DT | OSANETANT | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.